Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilaprazole

Drug Profile

Ilaprazole

Alternative Names: Aldenon; Aldenonc; IY-81149; Noltec; Yi Li An

Latest Information Update: 05 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Il-Yang
  • Developer Il-Yang; Livzon Group; Takeda
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 31 Oct 2018 Phase-III clinical trials in Gastro-oesophageal reflux in South Korea (PO) (NCT03444883)
  • 27 Feb 2018 Il-Yang Pharm plans a phase III trial for Gastro oesophageal reflux, in April 2018 (PO) (NCT03444883)
  • 01 Jan 2017 Il-Yang Pharm completes a phase I drug-drug interaction trial in Healthy volunteers in South Korea (PO) (NCT02998437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top